Context. Cancer pain can appear with spikes of higher intensity. Breakthrough cancer pain (BTCP) is the most common term for the transient exacerbations of pain, but the ability of the nomenclature to capture relevant pain variations and give treatment guidance is questionable.
Introduction
Cancer pain can be caused by the cancer itself or by cancer therapy. Tissue damage may occur in sites such as bone, viscera, and nerve structures and sometimes call for specific treatment strategies. Intermittent spikes of higher pain intensity may occur, most often named breakthrough cancer pain (BTCP) (1) . The definitions used for BTCP assume a stable or controlled background pain (1) . However, also when the background pain is not controlled, cancer pain may fluctuate.
The prevalence of BTCP varies between studies (2) . Factors other than differences in symptom and disease burden might influence the reported prevalence. These factors include differences in definitions and diagnostic criteria (3, 4) , and inclusion of patients with poorly controlled background pain (5) . 
Methods
A two-round international Delphi expert survey was performed from February to May 2015. The participants, identified by a literature search performed in PubMed using the same strategy as in a recent systematic review on BTCP (1), were the most frequent authors on the subject over the past ten years. Delphi surveys may have low response rates (11, 12) , and a predefined initial number of approximately 50 experts was chosen to ensure a final sample size large enough for valid results (13) (Fig. 1) . The authors and co-authors on BTCP articles were contacted by email and invited to participate in a web survey. Two reminders were mailed to non-responders in both rounds, and the survey was closed one week after the final reminder.
The selection of issues to be addressed was initially based upon areas with low degree of consensus identified in a systematic literature review on assessment and classification of BTCP (1) . These areas included the question of opioid medication as a prerequisite for the diagnosis of BTCP, the issue of controlled background pain and how to measure it, and the lack of a formal classification system. The authors of this paper further M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 discussed these issues and formulated twenty statements (Table 1) The study participants were asked to rate their agreement with the statements on an eleven point numeric rating scale (NRS 0-10), with the anchors, "do not agree at all" and "completely agree", respectively. Based on previous research and in accordance with the study protocol (14, 15) , the statements reaching a median score of less than seven (NRS 0-10) or an inter-quartile range (IQR) of more than three were reassessed, except for statements were the participants universally did not agree with the statement (median NRS 0). The median NRS rating and the IQR for each statement in the previous round were disclosed to the participants in the second round. According to a priori agreement and in line with recently published research (12, 15) , consensus was defined as a median NRS (0-10) score of seven or more and an IQR of three or less. The results are reported as medians and IQRs of the agreement with the statements (16) .
Results
Fifty-two authors and co-authors had published three or more papers on BTCP over the past ten years and were eligible for the study (Fig. 1) . The contact details were unavailable for four authors, therefore an invitation mail was sent to 48 potential participants.
Two authors declined participation due to lack of clinical experience, leaving 46 potential respondents. After two reminders, 27 respondents provided complete answers to the first round. After two reminders, 24 respondents provided complete answers to the second round.
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Consensus was reached for 11 statements in the first round (Table 1 ). In addition, there was a unison disagreement with two statements. After reassessment in the second round, consensus was reached for two more, resulting in consensus on 13 of 20 statements.
Regarding the statements on definitions, consensus was reached in the first round for:
"Transient cancer pain exacerbation is possible without significant background pain" (NRS In some former definitions, regularly administered opioid medication was suggested as a prerequisite for BTCP (17) . In more recent literature, this requirement has generally been abandoned (6, 7, 10, 18) . The current definitions of BTCP require the presence of a background pain, and that the background pain has an intensity below a defined level, e.g. and palliative medicine, and should capture clinically important data and be responsive to change over time (19) . Extensive work has been undertaken to identify meaningful cut-off points for pain intensity measurements, including pain exacerbation and pain relief, and different cut points and methods to measure changes in pain intensity have been suggested (20) (21) (22) (23) (24) (25) . The lack of consensus on the statements presenting specific cut-off points for BTCP intensity and meaningful changes in pain intensities must be interpreted in the light of the ongoing research. Also the definition of a controlled background pain is currently being discussed (26) , and the absence of consensus must be viewed against this background.
NRS (0-10) ≤ 4 (7)
Several papers have applied the criterion not more than "mild" intensity for a controlled background pain (6, 8, 18) . In even more recent research controlled background pain is defined as NRS(0-10) ≤ 4 (7), based on previous findings (24).
The international Delphi panel reached agreement on the statements implying that the best description of pain as controlled or in need for further treatment is the patient's satisfaction with the ongoing medication or wish for further medication, respectively. BTCP has been recognized as a spectrum of very different entities (6) . Within the international expert panel there was consensus that there are intermittent pain flares other than BTCP, and support for the idea of "episodic pain" as an overarching term for all such transient pain exacerbations. Episodic pain was previously suggested as a clinical entity by EAPC (27) . In a topical review preceding the latest update of the International Classification M A N U S C R I P T
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of Diseases (ICD-11), cancer pain is described as continuous (background pain) or intermittent (episodic pain) (28) , in line with the consensus reached in this study.
Different pain etiologies and pathophysiological mechanisms may call for different treatment modalities, as affirmed in this study. Although underused, single fraction radiotherapy is efficacious in palliating uncomplicated bone metastases (29) . Neuropathic pain, associated with an unpredictable response to conventional analgesic treatment, can potentially be relieved by addition of specific adjuvant drugs (15). Furthermore, episodic pain with visceral etiology is an important finding in patients with abdominal cancer (30) .
Also in the topical review preceding the latest ICD-11 update (28), the importance of pain etiology, pathophysiology, and body site is emphasized. Moreover, the principle of multiple parenting is introduced, allowing the same diagnosis to be subsumed under more than one category. In clinical practice, the diagnostic process can be guided by important symptom descriptors and PROMs followed by a symptom diagnosis with related pathophysiology and etiology (Fig. 2) .
Only approximately 50% of the eligible authors responded in both rounds. Although expected (11, 12) , this is a clear limitation of the study. And even though authors of papers on BTCP will have special insights in this field of research, a risk of including participants with limited clinical experience was present. Additionally, no input was obtained from the patients. 
